Reslizumab parenteral
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Infusions of reslizumab.
Drugs List
Therapeutic Indications
Uses
Severe eosinophilic asthma: Add-on maintenance treatment
Dosage
Adults
The recommended dose is 3mg/kg body weight by intravenous infusion every four weeks.
Additional Dosage Information
A double dose must not be administered if a dose has been missed on the planned date but the normal dose resumed as soon as possible and treatment is intended for long-term.
The need for continued therapy should be considered at least on an annual basis as determined by physician assessment of the patient's disease severity and level of control of exacerbations.
Administration
Solution for infusion should be administered intravenously over 20 to 50 minutes and may vary depending upon the volume of solution for infusion.
Contraindications
Children under 18 years
Hereditary fructose intolerance
Precautions and Warnings
Susceptibility to helminth infections
Breastfeeding
Glucose-galactose malabsorption syndrome
Pregnancy
Not suitable for acute treatment of asthma
Treat helminth infection before initiation of therapy
Treatment to be prescribed under the supervision of a specialist
Preparation contains sucrose
Record name and batch number of administered product
Monitor for hypersensitivity reactions during infusion
Monitor for hypersensitivity reactions for at least 30 mins after admin
Consider temporary discontinuation if helminth infection occurs
Discontinue if serious allergic or anaphylactic reaction occurs
Advise patient to consult physician if condition worsens / does not improve
Pregnancy and Lactation
Pregnancy
Use reslizumab with caution during pregnancy.
The manufacturer notes that it is preferable if administration of this medication is avoided as there is little data on the use of reslizumab in pregnant women, although animal studies do not indicate reproductive toxicity. Risks are unknown.
Lactation
Use reslizumab with caution during breastfeeding.
The manufacturer notes that animal studies show excretion of reslizumab in milk. It is unknown whether the drug is excreted in human milk but antibodies may be transferred via the mother's milk to the newborn baby during the first few days.
Side Effects
Anaphylactic reaction
Creatine phosphokinase increased
Myalgia
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: November 2020
Reference Sources
Summary of Product Characteristics: Cinqaero (reslizumab) 10mg/ml concentrate for solution for infusion. Teva Pharmaceuticals Ltd. Revised September 2019.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.